#gdr

Part 1 of many-

Cytiva wrote-

Investment in its molecular diagnostic component lab in Wales means more work with companies such as GENEDRIVE , a molecular diagnostics company. David Budd, CEO genedrive says, "Our R&D teams worked effectively together in combining

#gdr

Part 2 of many-

their expertise, experience, and technologies to deliver innovative PCR Kits based on Cytiva's 'Ready-to-Go' formulations. The speed at which we were able to move together was facilitated by many previous years of cooperative working."

#gdr

Part 3 of many-

Cytiva has had a critical role working with diagnostic developers during the COVID-19 pandemic. In total, over 50 million people have been PCR tested using components or services from Cytiva. Diagnostic components, such as nitrocellulose membranes,

#gdr

Part 4 of many-

are used in 18 immunoassay-based COVID-19 tests available today.

#gdr

Part 5 of many-

A multi-million dollar investment will be used partly to expand chemistry labs in Cardiff, Wales as well as establishing design labs in Germany and China.

#gdr

Just to tie up the info in a link have a read of the full page-

https://markets.ft.com/data/announce/detail?dockey=600-202010270400CANADANWCANADAPR_C4300-1